-New restrictions on opioids that make the proprietary Champion Pain Care Protocol (“the Protocol”), a non-pharmaceutical treatment plan licensed to the Company that is highly effective in reducing pain, attractive to patients, doctors and funding agencies.
48 Wall Street, 10th Floor,
New York, NY 10005
Champion Pain Care Corporation, a development stage company, operates as a pain management company. It offers the Champion Pain Care Protocol, a proprietary pain management protocol for the treatment and management of chronic pain, as well as other pain management treatments. The company’s protocol includes various treatment plans comprising physical examination by the attending doctor, blood testing, and urine drug screening; education for patients about the nature of their chronic pain; on-going interaction to support patient adherence to beneficial behavioral changes; relaxation training to reduce the effects or stress and anxiety, which can aggravate pain; amino acids and other dietary supplements to restore and maintain normal brain chemistry; and the reduction of cellular and joint inflammation. Its treatment plans also consists of the day and night time regimens to promote restorative sleep; use of electrotherapy stimulation to promote production and release of endorphin; topical medications for pain relief; and on-going counseling, telephone and on-line support, and checkups. The company was formerly known as OICCO Acquisition I, Inc. and changed its name to Champion Pain Care Corporation in August 2014. The company is based in New York, New York. Champion Pain Care Corporation is a subsidiary of Champion Care Corp.
LICENSE AGREEMENT dated as of February 1, 2013, between Champion Care Corp. (“Licensor”), a corporation incorporated under the laws of Ontario, Canada having its principal place of business at 307-208 Evans Avenue, Toronto, Ontario, Canada M8Z 1J7 and Champion Pain Care Corp. (“Licensee”), a Nevada corporation having its principal place of business at 123 West Nye Lane, Suite 129, Carson City, Nevada 89706.
Terrance George Owen, 68
Chairman, Bi-Optic Ventures, Inc.
Dr. Terrance G. Owen is Independent Director at Eastwood Bio-Medical Canada, Inc., Chief Executive Officer, CFO, Director & CAO at OICco Acquisition I, Inc., Independent Director at Pacific Paradym Energy, Inc., Chief Executive Officer at Nanotech Systems, Inc., Independent Director at Pacific Arc Resources Ltd., Independent Director at Sonoma Resources, Inc., Chairman at Bi-Optic Ventures, Inc., and Chief Executive Officer & Director at Champion Pain Care Corp. He is on the Board of Directors at Eastwood Bio-Medical Canada, Inc., OICco Acquisition I, Inc., Pacific Paradym Energy, Inc., Pacific Arc Resources Ltd., Sonoma Resources, Inc., Champion Care Corp., and Champion Pain Care Corp.
Dr. Owen was previously employed as President, Chief Executive Officer & Director by Vanc Pharmaceuticals, Inc., President & Director by Helix BioPharma Corp., and President by Helix Biotech Corp.
Nuvapharm | Pharmaceutical Inc.
This site may harm your computer.
Nuvapharm has changed it’s company name to Vancpharm. This page will automatically be redirected to our new company website http://www.vancpharm.com.
Vanc Pharmaceuticals Inc (NPH:Venture)
VANC Pharmaceuticals Receives NPNs from Health Canada for 4 Products
Nov 19 14
VANC Pharmaceuticals Inc. announced that it has received Natural Product Number (the “NPN”) approvals for: FerroHEME (heme-iron supplement), PEDIA-SAFE drops (multivitamin dietary supplement for infant and children), SennaLax (natural laxative) and T36 Ointment (disinfectant and corticosteroid). The NPN approvals allow Vanc to manufacture, market and sell all 4 products immediately. The Canadian market for these 4 products is estimated to be $90 million annually. Vanc plans to manufacture these products and start sales and marketing activities for them beginning in Q1-2015. FerroHEME-A natural, bio-identical and highly bio-available organic haemoglobin iron supplement. PEDIA-SAFE-Drops a liquid multivitamin dietary supplement scientifically formulated for infants and children to promote and ensure the optimal physiological growth and development. SennaLax -A stimulant laxative derived from Senna leaves for gentle, overnight relief of occasional constipation. T36 Ointment -An ointment for temporary relief of minor skin irritations, rashes, itching and redness due to eczema, insect bites, poison ivy, poison oak, poison sumac, contact dermatitis, seborrheic dermatitis, psoriasis.
Vanc Pharmaceuticals Inc. Receives Health Canada Approval for 22 Generic Molecules
Nov 18 14
Vanc Pharmaceuticals Inc. announced that it has received Notice of Compliance from Health Canada for 22 generic molecules. These 22 molecules will comprise of 51 dosage forms across various therapeutic categories; including both chronic (long term) therapy and acute (short term) therapy. The Notice of Compliance from Health Canada provides the authorization for Vanc to market and sell the generic molecules in Canada.
Vanc Pharmaceuticals Inc. Auditor Raises ‘Going Concern’ Doubt
Oct 28 14
Vanc Pharmaceuticals Inc. filed its Annual on Oct 28, 2014 for the period ending Jun 30, 2014. In this report its auditor, Meyers Norris Penny LLP – MNP LLP, gave an unqualified opinion expressing doubt that the company can continue as a going concern.